3 Stocks Improving Performance Of The Drugs Industry

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 91 points (-0.5%) at 16,894 as of Thursday, July 10, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 864 issues advancing vs. 2,123 declining with 163 unchanged.

The Drugs industry currently sits down 1.0% versus the S&P 500, which is down 0.4%. Top gainers within the industry include Celgene ( CELG), up 0.9%, and AbbVie ( ABBV), up 0.8%. On the negative front, top decliners within the industry include Sanofi ( SNY), down 1.2%, Valeant Pharmaceuticals International ( VRX), down 1.0%, Novartis ( NVS), down 0.8%, Allergan ( AGN), down 0.6% and Amgen ( AMGN), down 0.6%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3. GlaxoSmithKline ( GSK) is one of the companies pushing the Drugs industry higher today. As of noon trading, GlaxoSmithKline is up $0.27 (0.5%) to $54.14 on average volume. Thus far, 1.7 million shares of GlaxoSmithKline exchanged hands as compared to its average daily volume of 2.4 million shares. The stock has ranged in price between $53.84-$54.21 after having opened the day at $53.90 as compared to the previous trading day's close of $53.87.

GlaxoSmithKline plc creates, discovers, develops, manufactures, and markets pharmaceutical products, such as vaccines, over-the-counter medicines, and health-related consumer products worldwide. GlaxoSmithKline has a market cap of $129.5 billion and is part of the health care sector. Shares are up 0.9% year-to-date as of the close of trading on Wednesday. Currently there are 2 analysts who rate GlaxoSmithKline a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates GlaxoSmithKline as a buy. The company's strengths can be seen in multiple areas, such as its notable return on equity, increase in stock price during the past year and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full GlaxoSmithKline Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Shire ( SHPG) is up $2.22 (0.9%) to $237.30 on heavy volume. Thus far, 796,638 shares of Shire exchanged hands as compared to its average daily volume of 850,500 shares. The stock has ranged in price between $230.62-$239.66 after having opened the day at $232.38 as compared to the previous trading day's close of $235.08.

Shire plc, a biopharmaceutical company, together with its subsidiaries, researches, develops, licenses, manufactures, markets, distributes, and sells pharmaceutical products. Shire has a market cap of $45.8 billion and is part of the health care sector. Shares are up 66.4% year-to-date as of the close of trading on Wednesday. Currently there are 7 analysts who rate Shire a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Shire as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, notable return on equity, compelling growth in net income and good cash flow from operations. We feel these strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value. Get the full Shire Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Bristol-Myers Squibb Company ( BMY) is up $0.55 (1.1%) to $48.47 on average volume. Thus far, 3.7 million shares of Bristol-Myers Squibb Company exchanged hands as compared to its average daily volume of 8.9 million shares. The stock has ranged in price between $47.55-$48.48 after having opened the day at $47.64 as compared to the previous trading day's close of $47.92.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. Bristol-Myers Squibb Company has a market cap of $79.3 billion and is part of the health care sector. Shares are down 9.8% year-to-date as of the close of trading on Wednesday. Currently there are 9 analysts who rate Bristol-Myers Squibb Company a buy, 1 analyst rates it a sell, and 7 rate it a hold.

TheStreet Ratings rates Bristol-Myers Squibb Company as a buy. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, compelling growth in net income, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations and notable return on equity. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Bristol-Myers Squibb Company Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing